LILLY’S CYRAMZA (ramucirumab) GAINS 6th FDA-APPROVED ONCOLOGY INDICATION
Lilly continues to build out its oncology brand pharmaceutical franchise with new Cyramza indications
The U.S. Food and Drug Administration (FDA) has approved Cyramza (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. Erlotinib is the generic form of the original Genentech/Roche brand product Tarceva.
Cyramza widens market access and revenue streams with new indication
This latest of six FDA-approved cancer treatment indications for Cyramza will be well received by those oncologists, pulmonologists and other medical professionals involved with the treatment of lung cancer patients. Cyramza’s other oncology indications span specific types of colorectal, liver, lung and stomach cancer.
A 6th indication gives Cyramza a wider footprint in managed care organizations and other payer formularies which fortifies its market access position. The NSCLC market sector has approximately 70 oncology therapies vying for business through their brand and generic pharmaceutical manufacturers. With an FDA-approved indication in this category they are now more eligible to promote it and create an additional revenue stream.
Available by prescription only, Cyramza is a fully human monoclonal antibody (mAb) that is administered via IV infusion. Lilly already has a very successful mAb therapy on the market. Launched in 2016, Taltz (Ixekizumab) is used to treat a variety of autoimmune diseases. Over the course of 2019, it produced over $1.3 billion in sales.
Clinical information about NSCLC
Over 80% of the lung cancer cases diagnosed are NSCLC. NSCLC has three main subtypes that start with different cell types but are bundled together as they have similar treatments and expected outcomes:
- Large cell carcinoma
- Squamous cell carcinoma
Cyramza continues to grow as an oncology brand pharmaceutical franchise
Cyramza was initially launched in 2014. It originated in the pipeline of ImClone Systems, a Bridgewater, New Jersey company that Lilly acquired in 2008 for $6.5 billion in a highly competitive bidding duel with oncology powerhouse Bristol Meyers Squibb (NYSE: BMY).
Genentech’s Tarceva earned its first FDA approval in 2004. The product went generic in 2014. Genentech, based in South San Francisco, is a wholly-owned subsidiary of Roche AG based in Basel, Switzerland. Like Lilly, Roche (Swiss Exchange: ROG-CH OTCQX: RHHBY) is a global leader in the development of advanced medicine and generated about $64 billion in sales during 2019.
Eli Lilly is having a banner year in 2020
Lilly has cultivated a robust oncology portfolio including its latest new product, Retevmo (selpercatinib), which was approved for 3 separate cancer indications in May 2020. Lilly achieved another win in May 2020 with the FDA approval of its new Alzheimer’s diagnostic IV drug Tauvid (flortaucipir F18). The latest new indication for Cyramza extends their streak of good fortune. There is no doubt Lilly is looking forward to exceeding their 2019 sales that were approximately $22.3 billion.
Thank you for reading this story
Read my other articles about medical and healthcare business trends, content marketing and digital strategy, brand and product management, consumer wellness, managed care and market access strategy. Contact me today for your healthcare content writing and content strategy needs.
I have over 20 years of experience in the healthcare industry producing valuable healthcare content for audiences and customers spanning physicians, nurses, pharmacists plus pharmaceutical companies, medical technology manufacturers, healthcare provider organizations, managed care, investors, consumers and other stakeholders.
Visit and connect…
As a healthcare content writer, my work aligns with an organization’s voice, brand, SEO elements, marketplace and objectives. It establishes trust in their company and recognized value in its products and services that generates revenue.
This experience was earned through working at Walgreens, Pfizer, AbelsonTaylor, TAP (Takeda Abbott Partnership), Hospira Worldwide and Boston Software Systems.
To a large degree, my professional interests emulate my family which includes doctors, nurses, physician assistants and other clinicians plus those that are working in healthcare administration and commercial enterprises.